read all about it

RM research this month now covers PRR and has a Buy rating with a near term(within 12months) price target of 27c. Their report is on the Prima Website and is very comprehensive. The detail within the report provides analysis that shows that in the longer term the revenues could be astronomical if final approvals are achieved.

I have extracted a few paragraphs from this report that provides a bit of a feel from the report but there is much more in terms of projections as far as into the years beyond 2020. Within the body of these extracts I particularly latch onto this sentence:

"We believe this day has come and Prima Biomed has in their hands an answer that medical community and patients are looking for."

Read on to ascertain the context of the above quote.

"Prima Biomed Ltd
Australian Biotech with Phase II/III Cancer Vaccine, Clinical Data Will Drive Share Price in 2013 & 2014"

Prima Biomed, A Cancer Vaccine Player - We are initiating coverage of Prima Biomed (ASX: PRR) with a BUY recommendation and a Price Target of A$0.27. Company is developing an immunotherapy for ovarian cancer. While cancer vaccines have been in clinical trials for more than a decade, to date we have witnessed limited success with only one product (Provenge) approved by FDA in 2010 to treat prostate cancer in men that have not received chemotherapy. However, the efforts of companies and researchers were not for nothing as lots of data have been collected that would help one day to create a cancer vaccine that would overcome past difficulties.

We believe this day has come and Prima Biomed has in their hands an answer that medical community and patients are looking for.

Prima Has Answers to all The Questions - Company has put a lot of effort toward optimizing the choice of antigen; improving the vaccine delivery system to maximize the magnitude and quality of T-cell (“tumor killing” cells) response; selecting the right patient population and sequencing the treatment at the right time when the immune system still has a capacity to respond. Moreover Prima’s CVac has gross margins that a significantly above industry competition. Overall, we view Prima Biomed as a highly convincing story with (a) - product in a late stage development (Phase II/III); (b) - product for an indication with a high unmet medical need and limited competition; (c) - product that has an orphan drug status granted by an FDA that eases regulatory pathway and provides additional exclusivity; (d) - several near term catalysts.

Prima Will be on Investors’ Radar in 2013 - Prima’s share price performance was disappointing at the end of 2012 due to investors’ concerns with Phase II CAN-003 interim efficacy data. However, we believe the data was not mature enough to make any calls on the future success of Phase II/III CAN-004 trial and investors should be patient until full data release in 4Q 2013. In our view, interim immune monitoring data was more indicative of therapy’s potential as CVac patients demonstrated much higher T cell activity, meaning they produce more CD8+ tumor killer cells. We believe that full immune monitoring data to be released in 3Q13 and full CAN-003 efficacy data will drive the share price with a further upside from the release of Phase II/III CAN-004 interim data in 1H14."